कोशिश गोल्ड - मुक्त
Hotspots & growth opportunities in biomanufacturing
Chronicle Pharmabiz
|November 27, 2025
THE Indian bioeconomy has grown from US$ 10 billion in 2014 to US$ 165.7 billion in 2024, and is likely reach US$ 300 billion by 2030.
The country has also witnessed an exponential rise in biotech startups in the past decade, as shown in Figure 1 below: India witnessed an almost 200-fold increase in biotech startups in the past 10 years.
The launch of Government of India policies such as BIRAC funding schemes (BIG (Biotechnology Ignition Grant), SEED (Sustainable Entrepreneurship and Enterprise Development) and LEAP (Launching Entrepreneurs for Affordable Products), the BioE3 Policy (India's "Biotechnology for Economy, Environment, and Employment" policy) and e-platforms such as Startup India have significantly accelerated the growth of the innovation ecosystems for Indian biotech post-2017.
As shown in Figure 2, Karnataka, Tamil Nadu and Maharashtra are the leading biotech hubs in Indial. In September 2025, the Government of India launched High Performance Biomanufacturing Platforms, a joint initiative of the Department of Biotechnology (DBT) and the Biotechnology Industry Research Assistance Council (BIRAC).This newly launched network comprising advanced biofoundries and biomanufacturing hubs will use tools such as synthetic biology, omics technologies, artificial intelligence, machine learning to advance developments across the Indian biotech, healthcare, agriculture, energy, climate, and food industries.
India already has over 21 biofoundries, compared to a global hub of 100, which positions India as an important innovation hotspot in global biomanufacturing space.Key drivers and challenges impacting Indian biomanufacturing sector
The Indian Government is currently focused on six thematic sectors for driving biomanufacturing growth, which are shown below:
यह कहानी Chronicle Pharmabiz के November 27, 2025 संस्करण से ली गई है।
हजारों चुनिंदा प्रीमियम कहानियों और 10,000 से अधिक पत्रिकाओं और समाचार पत्रों तक पहुंचने के लिए मैगज़्टर गोल्ड की सदस्यता लें।
क्या आप पहले से ही ग्राहक हैं? साइन इन करें
Chronicle Pharmabiz से और कहानियाँ
Chronicle Pharmabiz
Devices sector raises concern over notification proposing fee for tests
THE medical devices industry has raised concern over the Department of Health and Family Welfares' draft notification introducing fee for test or evaluation of medical devices and mandating inclusion of licence number of sub contractor on the product labels. The Department published the draft notification on April 10, proposing various amendments to the Medical Devices Rules (MDR), 2017 including introduction of fee for test or evaluation of 11 types of tests or evaluation.
2 mins
April 30, 2026
Chronicle Pharmabiz
Panel asks DoP to take efforts to decrease imported content in medical devices
OBSERVING that a majority of the medical devices market is addressed by imports, the Parliamentary Panel on Chemicals and Fertilisers has recommended to the Department of Pharmaceuticals (DOP) to take measures including promotion of stronger collaboration among the industry, academic institutions and research organisations to accelerate indigenous development of advanced medical devices.
1 mins
April 30, 2026
Chronicle Pharmabiz
AI in endoscopy will improve detecting early-stage cancer markers
INDIA has been moving steadily towards better cancer care. However, many cancers in India are still detected late, especially those in the digestive system.
2 mins
April 30, 2026
Chronicle Pharmabiz
Telangana appoints DG of DCA as compounding authority
IN a significant move to streamline regulatory compliance under the newly enacted Jan Vishwas provisions, the Government of Telangana has officially designated the Director General (DG) of the state’s Drugs Control Administration (DCA), Shahnawas Quasim, as the 'Compounding Authority'.
2 mins
April 30, 2026
Chronicle Pharmabiz
AIOCD seeks PM's intervention against e-pharmacies
THE All India Organisation of Chemists & Druggists (AIOCD), representing over 12.40 lakh pharmacists and distributors, has formally petitioned Prime Minister Narendra Modi to intervene against the unregulated growth of e-pharmacies and predatory pricing by large corporate entities.
1 mins
April 30, 2026
Chronicle Pharmabiz
Shed The Cavalier Attitude
A Parliamentary Panel has recently asked the Department of Pharmaceuticals (DoP) to take corrective steps to remove any administrative and procedural delays related to the Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) scheme.
2 mins
April 30, 2026
Chronicle Pharmabiz
DCOIWA slams new DCGI recruitment rules, cites dilution of tech standards
THE Drugs Control Officers (I) Welfare Association (DCOIWA), the national body of drug regulatory officers in the country, has criticised the Union Heath Ministry's newly notified recruitment rules for the post of DCGI, labelling them as a serious policy lapse.
1 mins
April 30, 2026
Chronicle Pharmabiz
Experts highlight the need for data exclusivity to protect MSMES
EXPERTS have highlighted the need for clinical data exclusivity in order to protect MSME drug innovators in India.
2 mins
April 30, 2026
Chronicle Pharmabiz
Mid-sized hospitals in Tier-2 cities stranded in a financial vacuum: Expert
MID-sized hospitals in Tier-2 cities are currently trapped in a financial vacuum. This is because funding usually arrives either too early as venture capital or too late as a financial buyout, said Rakshith Rangarajan, equity fund manager, Inviga Investment Advisors.
2 mins
April 30, 2026
Chronicle Pharmabiz
Indian healthcare sector faces escalating cyber risks
INDIAN healthcare sector is confronting a surge in cyber threats as increasingly complex hospital IT ecosystems create multiple vulnerabilities for potential breaches.
2 mins
April 30, 2026
Listen
Translate
Change font size

